BC
TERN

Bridgefront Capital’s Terns Pharmaceuticals TERN Stock Holding History

Bridgefront Capital’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,316
Closed -$86K – 784
2024
Q3 		$86K Buy
+10,316
New +$84.9K 0.03% 495

Other funds holding TERN

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bridgefront Capital's TERN Position: Q4 2024 in Review

Bridgefront Capital sold out of Terns Pharmaceuticals (TERN) in Q4 2024, closing a stake of 10,316 shares — an estimated $86K sold.

Bridgefront Capital first reported a position in TERN in Q3 2024 and held it in 1 quarter. The position peaked at $86K in Q3 2024. 157 funds tracked by Wall St. Rank hold TERN as of Q4 2024.

  • Bridgefront Capital reported no remaining Terns Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Bridgefront Capital sold 10,316 Terns Pharmaceuticals shares in Q4 2024, an estimated $86K.
  • Bridgefront Capital first reported a position in Terns Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Bridgefront Capital's Terns Pharmaceuticals position peaked at $86K in Q3 2024.
  • 157 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2024.

Based on Bridgefront Capital's 13F filing for Q4 2024, filed 14 Feb 2025.